Ben Derman: One Recommendation I Make Over and Over is to Use a Prophylactic DOAC Instead of Aspirin
Ben Derman, Asst Professor at University of Chicago, posted on X:
“One recommendation I make over and over is to use a prophylactic DOAC instead of aspirin in newly diagnosed myeloma. Just choose a DOAC [they are getting much more affordable!]!
Risk scores lack validation for choosing VTE ppx.
The BENEFIT trial shows 6-month incidence of VTE was 0.8% in patients receiving ppx DOAC vs 5.6% with ppx heparin, and 9.8% in patients receiving aspirin.”
Title: Thromboembolism in transplant-ineligible multiple myeloma patients on triplet/quadruplet therapy: a post hoc analysis of BENEFIT trial
Authors:Emilie Chalayer, Corinne Frere, Elisabeth Daguenet, Thomas Lecompte, Bernard Tardy, Ilhame Bounouara, Manon Sapet, Arthur Bobin, Stephanie Harel, Olivier Decaux, Karim Belhadj, Cyrille Touzeau, Margaret Macro, Mohamad Mohty, Philippe Moreau, Jill Corre, Hervé Avet-Loiseau, Lionel Karlin, Thierry Facon, Aurore Perrot, Cyrille Hulin, Salomon Manier, Laurent Frenzel, Xavier Leleu

Read full article here.
Stay informed with Hemostasis Today.
-
May 18, 2026, 14:02Matteo Foschi: A Global Gathering for Stroke Innovation and Research at ESOC 2026
-
May 18, 2026, 14:01Who is the NBA? – Haemophilia Foundation Australia
-
May 18, 2026, 14:00Julie Makani: Partnership between Tanzania and the USA – Health Sciences
-
May 18, 2026, 13:58Alejandro González Veliz: Cardiology Enters the Era of Inflammation
-
May 18, 2026, 13:50Arshad-Ali Auhammad: Celebrating Youth Leadership in the Global Bleeding Disorders Community
-
May 18, 2026, 13:36Zain Khalpey: In Cardiovascular Medicine Flow Is Everything
-
May 18, 2026, 13:36George Adel: Advancing Stroke Management at El Mabara Hospital Through Collaborative ICU Engagement
-
May 18, 2026, 13:33Astha Thakkar: Three Things to Know Before Your IV Iron Infusion
-
May 18, 2026, 13:29Brian O Mahony: Ahead of the World Health Assembly in Geneva